Stem cells of the breast and cancer therapy

Women's Health

Volumn 6, Issue 2, 2010, Pages 205-219

  Groner, Bernd ^a   Vafaizadeh, Vida ^a   Brill, Boris ^a   Klemmt, Petra ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Breast cancer; Cancer stem cell; Epithelial mesenchymal transition; Mammary gland; Signaling in stem cells; Stem cell

Indexed keywords

ABC TRANSPORTER; ALPHA6 INTEGRIN; ANTINEOPLASTIC AGENT; BETA CATENIN; BETA1 INTEGRIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RETINOIC ACID; SONIC HEDGEHOG PROTEIN; STEM CELL FACTOR RECEPTOR; TRASTUZUMAB; WNT PROTEIN;

BREAST CANCER; BREAST CELL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL ACTIVITY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL STRUCTURE; CELL SURVIVAL; CELL TYPE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; LACTATION; METASTASIS POTENTIAL; MYOEPITHELIUM CELL; NONHUMAN; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL DESTRUCTION; TREATMENT RESPONSE;

ADULT; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; WOMEN'S HEALTH;

EID: 77649333232     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.5     Document Type: Review

References (115)

1. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer (2010) (Epub ahead of print).
2. Kelsey JL, Gammon MD, John EM: Reproductive factors and breast cancer. Epidemiol. Rev. 15(1), 36-47 (1993).
3. Smith GH: Stem cells, hormones, and mammary cancer. Adv. Exp. Med. Biol. 617, 69-78 (2008).
4. Lof M, Weiderpass E: Impact of diet on breast cancer risk. Curr. Opin. Obstet. Gynecol. 21(1), 80-85 (2009).
5. Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S: Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc. Natl Acad. Sci. USA 96(5), 2520-2525 (1999).
6. Vargo-Gogola T, Rosen JM: Modelling breast cancer: one size does not fit all. Nat. Rev. Cancer 7(9), 659-672 (2007).
7. Prat A, Perou CM: Mammary development meets cancer genomics. Nat. Med. 15(8), 842-844 (2009).
8. Lim E, Vaillant F, Wu D et al.: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers Nat. Med. 15(8), 907-913 (2009).
9. Pontier SM, Muller WJ: Integrins in mammary-stem-cell biology and breast-cancer progression - a role in cancer stem cells? J. Cell Sci. 122(Pt 2), 207-214 (2009).
10. Stingl J: Detection and analysis of mammary gland stem cells. J. Pathol. 217(2), 229-241 (2008).
11. Asselin-Labat ML, Vaillant F, Shackleton M, Bouras T, Lindeman GJ, Visvader JE: Delineating the epithelial hierarchy in the mouse mammary gland. Cold Spring Harb. Symp. Quant. Biol. 73, 469-478 (2008).
12. Smith GH, Medina D: A morphologically distinct candidate for an epithelial stem cell in mouse mammary gland. J. Cell Sci. 90 (Pt 1), 173-183 (1988).
13. Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu. Rev. Med. 58, 267-284 (2007).
14. Ailles LE, Weissman IL: Cancer stem cells in solid tumors. Curr. Opin. Biotechnol. 18(5), 460-466 (2007).
15. Fillmore CM, Kuperwasser C: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10(2), R25 (2008).
16. Tanei T, Morimoto K, Shimazu K et al.: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 15(12), 4234-4241 (2009).
17. Ward RJ, Dirks PB: Cancer stem cells: at the headwaters of tumor development. Annu. Rev. Pathol. 2, 175-189 (2007).
18. Trumpp A, Wiestler OD: Mechanisms of disease: cancer stem cells - targeting the evil twin. Nat. Clin. Pract. Oncol. 5(6), 337-347 (2008).
19. Kakarala M, Wicha MS: Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol. 26(17), 2813-2820 (2008).
20. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003).
21. Rossi DJ, Jamieson CH, Weissman IL: Stems cells and the pathways to aging and cancer. Cell 132(4), 681-696 (2008).
22. O'Brien CS, Farnie G, Howell SJ, Clarke RB: Are stem-like cells responsible for resistance to therapy in breast cancer? Breast Dis. 29, 83-89 (2008).
23. O'Brien CS, Howell SJ, Farnie G, Clarke RB: Resistance to endocrine therapy: are breast cancer stem cells the culprits? J. Mammary Gland Biol. Neoplasia 14(1), 45-54 (2009).
24. Polyak K: Is breast tumor progression really linear? Clin. Cancer Res. 14(2), 339-341 (2008).
25. Molyneux G, Regan J, Smalley MJ: Mammary stem cells and breast cancer. Cell. Mol. Life Sci. 64(24), 3248-3260 (2007).
26. Eirew P, Stingl J, Raouf A et al.: A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat. Med. 14(12), 1384-1389 (2008).
27. Tiede BJ, Owens LA, Li F, DeCoste C, Kang Y: A novel mouse model for non-invasive single marker tracking of mammary stem cells in vivo reveals stem cell dynamics throughout pregnancy. PLoS One 4(11), e8035 (2009).
28. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ: CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res. 8(1), R7 (2006).
29. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ: Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J. Cell Biol. 176(1), 19-26 (2007).
30. Kendrick H, Regan JL, Magnay FA et al.: Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 9, 591 (2008).
31. Oakes SR, Naylor MJ, Asselin-Labat ML et al.: The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev. 22(5), 581-586 (2008).
32. Brisken C, Heineman A, Chavarria T et al.: Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 14(6), 650-654 (2000).
33. Mallepell S, Krust A, Chambon P, Brisken C: Paracrine signaling through the epithelial estrogen receptor a is required for proliferation and morphogenesis in the mammary gland. Proc. Natl Acad. Sci. USA 103(7), 2196-2201 (2006).
34. Bouras T, Pal B, Vaillant F et al.: Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3(4), 429-441 (2008).
35. Lindeman GJ, Visvader JE, Smalley MJ, Eaves CJ: The future of mammary stem cell biology: the power of in vivo transplants. Breast Cancer Res. 10(3), 402; author reply, 403 (2008).
36. Shackleton M, Vaillant F, Simpson KJ et al.: Generation of a functional mammary gland from a single stem cell. Nature 439(7072), 84-88 (2006).
37. Taddei I, Deugnier MA, Faraldo MM et al.: β1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat. Cell Biol. 10(6), 716-722 (2008).
38. Brisken C, Duss S: Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective. Stem Cell Rev. 3(2), 147-156 (2007).
39. Stingl J, Eirew P, Ricketson I et al.: Purification and unique properties of mammary epithelial stem cells. Nature 439(7079), 993-997 (2006).
40. Smith GH, Medina D: Re-evaluation of mammary stem cell biology based on in vivo transplantation. Breast Cancer Res. 10(1), 203 (2008).
41. Ginestier C, Hur MH, Charafe-Jauffret E et al.: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007).
42. Raouf A, Zhao Y, To K et al.: Transcriptome analysis of the normal human mammary cell commitment and differentiation process Cell Stem Cell 3(1), 109-118 (2008).
43. Cho RW, Clarke MF: Recent advances in cancer stem cells. Curr. Opin. Genet. Dev. 18(1), 48-53 (2008).
44. Cobaleda C, Cruz JJ, González-Sarmiento R, Sánchez- García I, Pérez-Losada J: The emerging picture of human breast cancer as a stem cell-based disease. Stem Cell Rev. 4(2), 67-79 (2008).
45. Phesse TJ, Clarke AR: Normal stem cells in cancer prone epithelial tissues. Br. J. Cancer 100(2), 221-227 (2009).
46. Polyak K: Breast cancer: origins and evolution. J. Clin. Invest. 117(11), 3155-3163 (2007).
47. Charafe-Jauffret E, Ginestier C, Iovino F et al.: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69(4), 1302-1313 (2009).
48. Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003).
49. Leary RJ, Lin JC, Cummins J et al.: Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl Acad. Sci. USA 105(42), 16224-16229 (2008).
50. Leary RJ, Lin JC, Cummins J et al.: Functional classification analysis of somatically mutated genes in human breast and colorectal cancers. Genomics 91(6), 508-511 (2008).
51. Wood LD, Parsons DW, Jones S et al.: The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007) (5853).
52. Ali MA, Sjoblom T: Molecular pathways in tumor progression: from discovery to functional understanding. Mol. Biosyst. 5(9), 902-908 (2009).
53. Kouros-Mehr H, Bechis SK, Slorach EM et al.: GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13(2), 141-152 (2008).
54. Zhang M, Behbod F, Atkinson RL et al.: Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 68(12), 4674-4682 (2008).
55. Cicalese A, Bonizzi G, Pasi CE et al.: The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138(6), 1083-1095 (2009).
56. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE: The mammary progenitor marker CD61/p3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 68(19), 7711-7717 (2008).
57. Korkaya H, Wicha MS: HER-2, Notch, and breast cancer stem cells: targeting an axis of evil. Clin. Cancer Res. 15(6), 1845-1847 (2009).
58. Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS: Cancer stem cells in breast: current opinion and future challenges. Pathobiology 75(2), 75-84 (2008).
59. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 11(3), 1154-1159 (2005).
60. Yoo MH, Hatfield DL: The cancer stem cell theory: is it correct? Mol. Cells 26(5), 514-516 (2008).
61. Majeti R, Becker MW, Tian Q et al.: Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl Acad. Sci. USA 106(9), 3396-3401 (2009).
62. Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI: The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp. Mol. Pathol. 87(1), 1-11 (2009).
63. Korkaya H, Paulson A, Iovino F, Wicha MS: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27(47), 6120-6130 (2008).
64. Haq B, Geyer CE: Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. Womens Health (Lond. Engl.) 5(2), 135-147 (2009).
65. Turashvili G, Bouchal J, Burkadze G, Kolar Z: Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73(5), 213-223 (2006).
66. Klaus A, Birchmeier W: Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 8(5), 387-398 (2008).
67. Buono KD, Robinson GW, Martin C et al.: The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev. Biol. 293(2), 565-580 (2006).
68. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 6(6), R605-15 (2004).
69. Farnie G, Clarke RB: Mammary stem cells and breast cancer - role of Notch signalling. Stem Cell Rev. 3(2), 169-175 (2007).
70. Yamaguchi N, Oyama T, Ito E et al.: NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res. 68(6), 1881-1888 (2008).
71. Liu S, Dontu G, Mantle ID et al.: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66(12), 6063-6071 (2006).
72. Groner B, Lucks P, Borghouts C: The function of Stat3 in tumor cells and their microenvironment. Semin. Cell Dev. Biol. 19(4), 341-350 (2008).
73. Wagner KU, Rui H: Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J. Mammary Gland. Biol. Neoplasia 13(1), 93-103 (2008).
74. Walker SR, Nelson EA, Zou L et al.: Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol. Cancer Res. 7(6), 966-976 (2009).
75. Sansone P, Storci G, Tavolari S et al.: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117(12), 3988-4002 (2007).
76. Debeb BG, Xu W, Woodward WA: Radiation resistance of breast cancer stem cells: understanding the clinical framework. J. Mammary Gland Biol. Neoplasia 14(1), 11-17 (2009).
77. Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA: Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin. Oncol. 35(4), 401-409 (2008).
78. Ginestier C, Wicinski J, Cervera N et al.: Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 8(20), 3297-3302 (2009).
79. Zhao C, Chen A, Jamieson CH et al.: Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458(7239), 776-779 (2009).
80. Shih IeM, Wang TL: Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res. 67(5), 1879-1882 (2007).
81. Hao L, Rizzo P, Osipo C et al.: Notch-1 activates estrogen receptor-α-dependent transcription via IKKα in breast cancer cells. Oncogene 29(2), 201-213 (2010).
82. Borghouts C, Kunz C, Groner B: Peptide aptamer libraries. Comb. Chem. High Throughput Screen. 11(2), 135-145 (2008).
83. Smith GH, Chepko G: Mammary epithelial stem cells. Microsc. Res. Tech. 52(2), 190-203 (2001).
84. Desrivières S, Kunz C, Barash I, Vafaizadeh V, Borghouts C, Groner B: The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J. Mammary Gland. Biol. Neoplasia 11(1), 75-87 (2006).
85. Boulanger CA, Smith GH: Reprogramming cell fates in the mammary microenvironment. Cell Cycle 8(8), 1127-1132 (2009).
86. Booth BW, Mack DL, Androutsellis-Theotokis A, McKay RD, Boulanger CA, Smith GH: The mammary microenvironment alters the differentiation repertoire of neural stem cells. Proc. Natl Acad. Sci. USA 105(39), 14891-14896 (2008).
87. Medina D: Breast cancer: the protective effect of pregnancy. Clin. Cancer Res. 10(1 Pt 2), 380S-384S (2004).
88. Medina D: Mammary developmental fate and breast cancer risk. Endocr. Relat. Cancer 12(3), 483-495 (2005).
89. Boulanger CA, Wagner KU, Smith GH: Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-β1 expression. Oncogene 24(4), 552-560 (2005).
90. Dontu G, Liu S, Wicha MS: Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 1(3), 207-213 (2005).
91. Matulka LA, Triplett AA, Wagner KU: Parity-induced mammary epithelial cells are multipotent and express cell surface markers associated with stem cells. Dev. Biol. 303(1), 29-44 (2007).
92. Shipitsin M, Polyak K: The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab. Invest. 88(5), 459-463 (2008).
93. Laffin B, Wellberg E, Kwak HI et al.: Loss of singleminded-2s in the mouse mammary gland induces an epithelial-mesenchymal transition associated with up-regulation of slug and matrix metalloprotease 2. Mol. Cell. Biol. 28(6), 1936-1946 (2008).
94. Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9(4), 265-273 (2009).
95. Mani SA, Guo W, Liao MJ et al.: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704-715 (2008).
96. Hollier BG, Evans K, Mani SA: The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mammary Gland Biol. Neoplasia 14(1), 29-43 (2009).
97. Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Barsky SH: ERα suppresses slug expression directly by transcriptional repression. Biochem. J. 416(2), 179-187 (2008).
98. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8(10), 755-768 (2008).
99. Li X, Lewis MT, Huang J et al.: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100(9), 672-679 (2008).
100. Kvinlaug BT, Huntly BJ: Targeting cancer stem cells. Expert Opin. Ther. Targets 11(7), 915-927 (2007).
101. Gupta PB, Onder TT, Jiang G et al.: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4), 645-659 (2009).
102. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12(10), 1167-1174 (2006).
103. Malanchi I, Peinado H, Kassen D et al.: Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 452(7187), 650-653 (2008).
104. Velculescu VE: Defining the blueprint of the cancer genome. Carcinogenesis 29(6), 1087-1091 (2008).
105. Krizhanovsky V, Lowe SW: Stem cells: the promises and perils of p53. Nature 460(7259), 1085-1086 (2009).
106. Hong H, Takahashi K, Ichisaka T et al.: Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460(7259), 1132-1135 (2009).
107. Zhao XY, Li W, Lv Z et al.: iPS cells produce viable mice through tetraploid complementation. Nature 461(7260), 86-90 (2009).
108. Gaspar-Maia A, Alajem A, Polesso F et al.: Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 460(7257), 863-868 (2009).
109. Tanos T, Brisken C: What signals operate in the mammary niche? Breast Dis. 29, 69-82 (2008).
110. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67(8), 3560-3564 (2007).
111. Kim MR, Choi HK, Cho KB, Kim HS, Kang KW: Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci. 100(10), 1834-1841 (2009).
112. Hiscox S, Jordan NJ, Smith C et al.: Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res. Treat. 115(1), 57-67 (2009).
113. Dylla SJ, Beviglia L, Park IK et al.: Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3(6), E2428 (2008).
114. Kasper M, Jaks V, Fiaschi M, Toftgård R: Hedgehog signalling in breast cancer. Carcinogenesis 30(6), 903-911 (2009).
115. Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA: Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol. Histopathol. 24(3), 385-398 (2009).